CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Top-line data from an open-label Phase 2 study of 216 people with mild-to-moderate Alzheimer’s disease treated with simufilam tablets at 100 mg twice daily for a year revealed a minimal decline in cognitive ability overall, as measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog-11). Simufilam was found to be safe and well tolerated, and it alleviated depression and dementia-related behaviors in patients, which were two exploratory trial goals.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
